Rindopepimut: Phase II started

Celldex began the double-blind, U.S. Phase II ReACT trial of 500 µg rindopepimut plus granulocyte macrophage colony-stimulating factor (GM-CSF) given 3 times 2 weeks apart followed by a monthly injection in about 95 patients. About 70 Avastin bevacizumab-naïve patients will receive either rindopepimut plus GM-CSF in combination with Avastin or Avastin plus keyhole limpet hemocyanin (KLH). About 25 Avastin-refractory patients will receive rindopepimut plus GM-CSF in combination with Avastin. ...